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Abstract: Herbomineral formulations have increased in recognition and popularity due to their high safety and better 
therapeutic action. A new proprietary herbomineral formulation was formulated with a mixture of the herbal root extract of 
ashwagandha and three minerals viz. zinc, magnesium, and selenium. The aim of the study was to evaluate the 
immunomodulatory potential of Biofield Energy Healing (The Trivedi Effect
®
) on the test formulation when applied to 
splenocyte cells isolated from the Biofield Treated mice. The test formulation was divided into two parts. One part was 
denoted as the control without any Biofield Energy Treatment. The other part was defined as the Biofield Energy Treated 
sample, which received the Biofield Energy Healing Treatment remotely by seven renowned Biofield Energy Healers. A 
wide concentration range (0.00001053 to 10.53 µg/mL) of the test formulation was used to determine non-cytotoxic 
concentrations using MTT assay. Further, the expression of pro-inflammatory cytokines (TNF-α, MIP-1α, and IL-1β) was 
determined by ELISA method. The test formulation was evaluated and found to be safe up to 1.053 µg/mL with a 
percentage cell viability range of 73% to 97% using MTT assay. The Biofield Treated formulation improved the cell 
viability up to 6.61% compared with the untreated test formulation. TNF-α expression was significantly inhibited by 
16.72% at 0.1053 µg/mL compared with the untreated test formulation, however expression was significantly altered by 
53.67% and 25.62% at 0.01053 and 1.053 µg/mL, respectively compared to the untreated test formulation. TNF-α 
expression was also suppressed in the Biofield Treated test formulation at 0.001053 and 0.1053 µg/mL by 4.0% and 8.56%, 
respectively as compared with the vehicle control. MIP-1α suppression was reported in the Biofield Treated test formulation 
at 0.00001053 to 1.053 µg/mL by 8.43%, 22.02%, 21.92%, 20.54%, 5.40%, and 19.82%, respectively compared with the 
vehicle control. However, the Biofield Treated formulation further exhibited substantial suppression of MIP-1α at 
0.0001053, 0.001053, 0.01053, and 0.1053 µg/mL by 13.50%, 7.38%, 36.83% (p≤0.001), and 2.53%, respectively 
compared with the untreated test formulation. In addition, significant inhibition of IL-1β secretion was reported in the 
Biofield Treated formulation at 0.0001053, 0.001053, 0.01053, and 0.01053 µg/mL by 32.40%, 14.99%, 60.42%, and 
15.15%, respectively compared with the untreated test formulation. The Biofield Energy Healing Treatment significantly 
potentiated the immunosuppressive effect of the test formulation in Biofield Treated mouse splenocytes, which can be used 
for autoimmune and inflammatory diseases, stress management and anti-aging by improving overall health. 
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1. Introduction 
The traditional systems of medicine widely use herbal 
drugs for many biological activities, but there are limited 
experimental studies based upon herbomineral formulations 
that combine herbs or plant extracts with minerals. Medicinal 
plants and minerals have been widely reported to have many 
healing properties including anti-inflammatory, anti-diabetic, 
and anti-stress activities, as well as improving overall health 
and the immune system [1, 2]. The immunomodulatory 
activity of herbal medicine can be potentiated with the 
presence of important minerals. These combination products 
are rapidly gaining attention due to their low toxicity and 
better bioavailability [3]. A newly formulated herbomineral 
formulation with improved immunomodulatory activity 
could be an advancement for pharmaceutical companies with 
respect to nutritional supplements. However, significant anti-
inflammatory activity is always an important target for any 
new herbomineral formulation [4]. Although the global 
market has different anti-inflammatory, analgesic, and 
immunomodulatory potential formulations with high 
efficacy, they are unfortunately unsuitable for many patients 
due to their limited potency, less tolerance, and adverse 
effects, etc. In the search of some novel formulation, a new 
proprietary herbomineral formulation was formulated using 
the root extract of the important medicinal plant Withania 
somnifera (ashwagandha), along with three minerals viz. zinc 
chloride, magnesium gluconate, and sodium selenate. The 
beneficial effects of the test formulation might be attributed 
to the immunomodulatory potential of each of the individual 
components [5-8]. For example, ashwagandha belongs to the 
family Solanaceae and is commonly used in alternative 
therapies for its immunomodulatory, antitumor, and 
antibacterial effects, and much more. This is due to the 
presence of pharmacologically active molecules like 
withanolides [9-11]. Additionally, it has been well-
documented that minerals such as selenium, zinc, and 
magnesium have significant importance in the modulation of 
the immune system and have been found to have strong 
immunomodulatory potential [6]. These formulations can be 
used for better therapeutic effect in immune compromised 
patients affected with cardiovascular diseases, age and stress 
related diseases, cancer, and autoimmune disorders. Along 
with the herbomineral formulations, the Biofield Energy 
Healers in this study have used energy medicine (Biofield 
Energy Healing Treatment) as a complementary and 
alternative approach to study the impact of Biofield Energy 
Treatment on the herbomineral formulation for its 
immunomodulatory potential with respect to the pro-
inflammatory cytokines in splenocyte cells isolated from the 
biofield energy treated mice. 
Amidst the broad field of Complementary and Alternative 
Medicine (CAM), there have been a substantial amount of 
scientific reports that show the beneficial effects of Biofield 
Energy Healing Therapy. However, the effect of Biofield 
Energy Treatment showed beneficial results to enhance the 
immune function of cervical cancer patients using therapeutic 
touch [12], massage therapy [13], etc. Biofield Energy 
Therapies have been practiced worldwide recently with 
significant therapeutic outcomes, such as enhanced personal 
well-being in the case of cancer patients [14], improved 
functional ability in arthritis patients [15], and decreased pain 
and anxiety [16]. The National Center of Complementary and 
Integrative Health (NCCIH) has recognized and accepted 
Biofield Energy Healing as a complementary and alternative 
medicine (CAM) health care approach in addition to other 
therapies, medicines and practices such as naturopathy, 
natural products, homeopathy, mindfulness, meditation, yoga, 
deep breathing, Tai Chi, Reiki, Qi Gong, 
chiropractic/osteopathic manipulation, massage, special diets, 
progressive relaxation, guided imagery, cranial sacral therapy 
acupressure, acupuncture, relaxation techniques, 
hypnotherapy, rolfing structural integration, movement 
therapy, pilates, Ayurvedic medicine, traditional Chinese 
herbs and medicines, healing touch, essential oils, 
aromatherapy, and applied prayer (as is common in all 
religions, like Buddhism, Christianity Hinduism, Judaism 
and Buddhism). Human Biofield Energy has subtle energy 
that has the capacity to work in an effective manner [17, 18]. 
Biofield Energy Healing Treatment (The Trivedi Effect
®
) had 
significant impact in the transformation of living organisms 
and nonliving materials such as medical science [19, 20], 
microbiology [21-24], genetics and biotechnology [25, 26], 
nutraceuticals [27-28], agricultural science and livestock [29-
32], and materials science [33-35]. 
This experiment was designed to evaluate the impact of 
Biofield Energy Healing (The Trivedi Effect
®
) Treatment on 
the new herbomineral formulation for immunomodulatory 
potential after co-incubation with the isolated splenocyte 
cells from the Biofield Energy Treated mice. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
The test formulation component ashwagandha (Withania 
somnifera) root extract powder (≥ 5% of total withanolides) 
was procured from Sanat Products Ltd., India. Zinc chloride 
and magnesium (II) gluconate hydrate were procured from 
Tokyo Chemical Industry Co., Ltd. (TCI), Japan. Sodium 
selenate was procured from Alfa Aesar, USA. Other 
experimental chemicals such as lipopolysaccharide (LPS), 3-
(4, 5-diamethyl-2-thiazolyl) 2, 5 diphenyl-2 H-tetrazolium) 
(MTT), Roswell Park Memorial Institute (RPMI-1640), L-
glutamine, penicillin, streptomycin, 4-(2-hydroxyethyl)-1-
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piperazineethanesulfonic acid (HEPES), 2- mercaptoethanol, 
concanavalin A (Con-A), rapamycin, NaHCO3, and EDTA 
were purchased from Sigma Chemical Corp. (St. Louis, MO), 
a subsidiary of Sigma-Aldrich Corporation. ELISA (enzyme-
link immunosorbent assay) assay kits for all cytokines tumor 
necrosis factor alpha (TNF-α), macrophage inflammatory 
protein-1α (MIP-1α), and interleukin-1 beta (IL-1β) were 
purchased from R&D systems, USA. Fetal bovine serum 
(FBS) was purchased from GIBCO, USA. All other 
chemicals used in the experiment were of analytical grade 
available in India. 
2.2. Test Formulation and Reference Standard 
The test formulation comprised of a combination of four 
ingredients viz. ashwagandha root powder extract, zinc 
chloride, sodium selenate, and magnesium gluconate. LPS 
was used as an inflammatory stimulant, while Con-A and 
rapamycin were used as the reference standard (positive 
control) for immunostimulatory and immunosuppressive 
action, respectively in the splenocyte assay. 
2.3. Experimental Animal 
C57BL/6 male mice (8 weeks old, 22 gm body weight) 
were purchased from Vivo Bio Tech Ltd., Hyderabad, India 
and acclimatized for one week prior to the experiments. The 
mice were maintained under controlled conditions with a 
temperature of 22 ± 3°C, humidity of 30% to 70% and a 12 
hours of light or 12 of hours dark cycle and rodent laboratory 
diet and drinking tap water were provided ad libitum. All the 
procedures were in strict accordance with the Guide for the 
Care and Use of Laboratory Animals published by the US 
National Institutes of Health. The approval of the 
Institutional Animal Ethics Committee was obtained prior to 
carrying out the animal experiment. 
2.4. Biofield Energy Healing Strategies 
The herbomineral test formulation was divided into two 
parts. One part of the herbomineral formulation did not 
receive any sort of treatment and was defined as the control 
group, while another part received the Biofield Energy 
Treatment and was defined as the Biofield Treated test 
formulation. Further, one group of mice received the Biofield 
Energy Treatment per se by the Biofield Energy Healers 
under similar conditions, which were used to isolate the 
splenocyte cells as per the study design (Figure 1). These 
isolated splenocyte cells were known as the Biofield Treated 
splenocyte cells. The Biofield Energy Healing Treatment 
(The Trivedi Effect
®
) was provided by the group of seven 
Biofield Energy Healers, six of which were remotely located 
in the U.S.A. and one of which was remotely located in 
Canada, while the test formulation was located in the 
research laboratory of Dabur Research Foundation near New 
Delhi in Ghaziabad, India, and kept under standard 
laboratory conditions. This treatment was provided for 5 
minutes through the Biofield Energy Healers’ unique Energy 
Transmission process (The Trivedi Effect
®
), administered 
remotely to the test formulation. Similarly, the control sample 
was subjected to “sham” healers under the same laboratory 
conditions for 5 minutes. The sham healer did not have any 
knowledge about the Biofield Energy Treatment. After that, 
the Biofield Energy Treated and untreated samples were kept 
in similar sealed conditions and used for the in vitro study on 
splenocyte cells for cytokines estimation. 
 
Figure 1. Schematic experimental design of the Biofield Energy Healing 
Treatment. 
2.5. Experimental Design 
The experimental study was divided into 7 groups. Group 
1 consisted of splenocyte cells isolated from the Biofield 
Energy Treated animal without LPS and was denoted as the 
negative control. Group 2 served as a stimulant group that 
included similar cells with LPS. Group 3 included the same 
isolated splenocyte cells with LPS along with the vehicle 
(0.005% DMSO) and was denoted as the vehicle control. 
Groups 4 and 5 were defined as the positive controls i.e. 
Con-A (0.5 µg/mL) and rapamycin (1 nM and 10 nM), 
respectively. Group 6 and 7 were denoted as the test item 
groups that included splenocyte cells (isolated from the 
Biofield Energy Treated animal) with LPS along with the 
untreated and Biofield Energy Treated test formulation, 
respectively at concentrations 0.00001053 to 10.53 µg/mL. 
After 48 hours of incubation, supernatants were analyzed for 
the secreted levels of TNF-α, MIP-1α, and IL-1β using 
ELISA (enzyme-linked immunosorbent assay) as per the 
manufacturer’s instructions. Concentrations were determined 
in triplicate wells of each sample. 
2.6. Isolation of Murine Splenocytes 
The Biofield Energy Treated C57BL/6 male mice were 
sacrificed and their spleens were aseptically removed and 
ground by passing through a sterile plastic strainer under 
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aseptic conditions. After the cells were centrifuged twice at 
1000 g for 5 minutes, erythrocytes were lysed by lysis buffer 
(0.15 M NH4Cl, 0.01 M NaHCO3, and 0.1 mM EDTA, pH 
7.4) and then the cell pellets were washed twice with RPMI-
1640 medium. Further, the cells were resuspended in 
complete RPMI-1640 medium (RPMI 1640 medium plus 
10% fetal bovine serum, 2 mM glutamine, 100 IU/mL of 
penicillin and streptomycin, 15 mM HEPES and 50 mM 2-
mercaptoethanol). The cell counts were performed using a 
hemocytometer and cell viability was determined using the 
trypan-blue dye exclusion technique with the results showing 
≥95% of viable cells. The cells were cultured in 96-well 
tissue culture plates with 0.2 x 10
6
 cells per well. They were 
incubated at 37°C in a humidified atmosphere of 5% CO2 for 
the indicated period [36]. 
2.7. Cell Culture and Test Item Treatment 
The splenocyte (0.2 x 10
6
 cells per well) cells isolated 
from the Biofield Energy Treated mice were grown in 96-
well culture plates using RPMI-1640 medium supplemented 
with 10% FBS, 100 units/mL of penicillin, and 100 µg/mL of 
streptomycin. LPS (50 ng/mL) induced splenocyte cells 
cultures were grown for 48 hours at 37°C in a humidified 
CO2 incubator (5% CO2). The effect of cytotoxicity of the 
test formulation was tested by treating cells with different 
concentrations of the test formulation in RPMI-1640 
medium. The various concentrations of the test formulation 
were used i.e. 0.00001053 µg/mL to 10.53 µg/mL in the 
presence of inflammatory stimulus (LPS) for cell viability 
assay. The respective vehicle controls (DMSO) were kept in 
the assay for comparison. 
2.8. Cytotoxicity by MTT Assay 
The effect of the test formulation at the concentration 
range of 0.00001053 µg/mL to 10.53 µg/mL was tested for 
cell viability assay using 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay. The number of 
viable cells were determined by the ability of mitochondria to 
convert MTT to formazan dye. Splenocyte cells isolated from 
the Biofield Energy Treated mice were cultured overnight in 
96-well plates, at a density of 0.2 x 10
6
 cells per well. After 
treatment with the test formulation and incubation period, the 
medium was removed. 20 µL of 5 mg/mL MTT was then 
added to each well and incubated for 3 hours further at 37ºC 
in a humidified 5% CO2 atmosphere. The cells were 
centrifuged and supernatants were removed. The cell pellets 
in each well were resuspended in 150 µL of DMSO to 
dissolve formazan crystals. The optical density of each well 
was read at 540 nm using BioTek Reader (SIAFRT/Synergy 
HT multimode reader, US). 
The effect of the test formulation on the cell viability of 
splenocyte cells was determined as equation (1): 
%	Cell	viability = 100 −%	cytotoxicity              (1) 
Where; % cytotoxicity = [(O.D. of control cells – O.D. of 
cells treated with the test formulation)/O.D. of control 
cells]*100. 
The concentration that resulted in >72% viability was 
selected for subsequent cytokine estimation. 
2.9. Determination of Cytokines (TNF-Α and IL-1β) and 
Chemokine (MIP-1α) Using ELISA 
The in-vitro activity of the test formulations was estimated 
on the mice splenocyte cells for the production of TNF-α, 
MIP-1α, and IL-1β using enzyme-linked immunosorbent 
assay (ELISA). The ELISA plates were coated with an 
antibody in a coating buffer at the recommended 
concentration and kept overnight at 4°C. After washing with 
PBS-T (PBS with 0.05% Tween 20), the plates were blocked 
with assay diluent for at least 2 hours at room temperature. A 
total of 100 µL culture supernatant from different 
experimental samples and standards were incubated 
overnight at 4°C and, after three washes, biotinylated anti-
mice cytokine (TNF-α, MIP-1α, and IL-1β) antibodies at the 
recommended concentrations were incubated for 1 hour at 
room temperature and the plates were incubated for 45 
minutes at room temperature with gentle shaking. The plates 
were again washed 3 times and then 100 µL of horseradish 
per-oxidase (HRP)–streptavidin conjugate solution was 
added and the plates were incubated for 45 minutes at room 
temperature with gentle shaking. Next, the plate wells were 
washed 3 times as previous and 100 µL of 3,3,5,5'-
tetramethylbenzidine (TMB) one-step substrate reagent was 
added, followed by a 30-minute incubation at room 
temperature in the dark. Further, 50 µL of 0.2 mole/L 
sulphuric acid was added to each well to stop the reaction 
and the plates were read for absorbance at 450 nm using a 
BioTek Reader (SIAFRT/Synergy HT multimode reader). 
Standards were run in parallel to the samples, and the 
concentrations were determined in triplicates for each sample 
[37]. 
2.10. Statistical Analysis 
Data were expressed as mean ± SEM and were subjected 
to Student’s t-test for two group comparison. Statistical 
significance was considered at p≤0.05. 
3. Results and Discussion 
3.1. MTT Assay on Splenocyte Cells 
The splenocyte cells isolated from the Biofield Energy 
Treated mice were studied for viability assay after exposure 
of the test formulation using MTT cell viability assay after 48 
hours of incubation. The cell viability results are summarized 
in Figure 2. The results showed the % cell viability was 
altered after the Biofield Energy Healing Treatment in all the 
tested concentrations of the herbomineral test formulation. 
The untreated cells isolated from the Biofield Treated 
mice, LPS, and Con-A group showed 100%, 187.44%, and 
160.47% cell viability, respectively, while the positive 
control (rapamycin) group showed percentage cell viability 
as 81.30% and 78.70% at concentrations 1 and 10 nM, 
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respectively in the presence of LPS (0.5 µg/mL). Con-A and 
rapamycin showed immunostimulatory and 
immunosuppressive action, respectively, and were used as 
positive controls in the experiment. The test formulation 
concentrations range from 0.00001053 to 10.53 µg/mL were 
selected for the cell viability assay on the Biofield Treated 
splenocyte cells, and concentrations up to 1.053 µg/mL were 
found to be safe with percentage viability ranging from 
72.91% to 97.54%. Out of the six tested concentrations, the 
cell viability was increased by 3.17%, 5.07%, 2.77%, and 
6.61% in the Biofield Treated test formulation i.e. at 
0.0001053, 0.01053, 0.1053, and 1.053 µg/mL, respectively, 
while two concentrations showed decreased cell viability at 
0.00001053 and 0.01053 µg/mL with respect to the untreated 
test formulation. 
 
Figure 2. MTT assay in splenocyte cells (isolated from the Biofield Treated mice) after 48 hours of treatment with different test formulation concentrations in 
the presence of 0.5 µg/mL LPS. The absorbance of the MTT formazan was determined at 540 nm in an ELISA reader. Cell viability was defined as the 
absorbance ratio (expressed as a percentage) of the test formulation treated cells relative to the untreated vehicle control group. 
MTT assay suggests that the concentrations of the test 
formulation were found safe up to 1.053 µg/mL with respect 
to the viability of splenocyte cells. However, the viability 
percentage was significantly increased after the Biofield 
Energy Treatment on the test formulation. This cell viability 
assay defines metabolic activity by evaluating the activity of 
succinate dehydrogenase, a mitochondrial enzyme. MTT 
assay is widely used in the in vitro evaluation of the cell 
toxicity for any test formulations, and is regarded as a more 
rapid, less costly, less time consuming, and non-radioactive 
method as compared with the other assays. This assay 
displays cell proliferation results on the basis of cell growth 
and metabolic activity [38]. 
3.2. Effect of the Biofield Energy Treated Test Formulation 
on Cytokines Expression (TNF- α and IL-1β) and 
Chemokine (MIP-1α) in Biofield Treated Mouse 
Splenocyte Cells 
The effect of the test formulation was evaluated for pro-
inflammatory cytokines and chemokines levels in the 
Biofield Treated splenocyte cells. Pro-inflammatory 
cytokines and chemokines play important roles in 
inflammation, immune modulation, and lymphocyte 
activation. Therefore, six concentrations were examined for 
the expression of TNF-α, MIP-1α and IL-1β in the splenocyte 
cells isolated from the Biofield Treated animals. The effect of 
the test formulation on pro-inflammatory cytokines was 
estimated after 48 hours of incubation with the test 
formulation using ELISA assay. 
3.2.1. Estimation of TNF-α Expression 
The results of TNF-α expression in the splenocyte cells of 
the Biofield Treated mice with respect to the test formulation 
are represented in Figure 3. At all the tested concentrations, 
both the untreated and Biofield Energy Treated formulation 
groups showed altered expressions of TNF-α. The untreated 
cells, LPS, Con-A, and vehicle control groups showed values 
of TNF-α as 100.14, 191.24, 255.60, and 208.19 pg/mL, 
respectively. At two different concentrations i.e. at 1 and 10 
nM, the rapamycin group showed TNF-α expression as 
158.48 and 184.91 pg/mL, respectively. 
However, the Biofield Energy Treated test formulation 
showed increases in the expression of TNF-α at five 
concentrations as compared with the untreated formulation. 
The significant alterations (p≤0.01) were reported in the 
Biofield Energy Treated formulation at concentrations 
0.01053 and 1.053 µg/mL, and the levels were increased by 
53.67% and 25.62%, respectively in comparison to the 
untreated test formulation. At concentration 0.1053 µg/mL, 
TNF-α was found to be suppressed by 16.72% in the Biofield 
Energy Treated formulation as compared with the untreated 
test formulation. On the other hand, the decreased expression 
of TNF-α in the untreated formulation group with respect to 
the vehicle control was reported at 0.00001053, 0.001053, 
0.01053, and 1.053 µg/mL by 7.18%, 19.05%, 6.90%, and 
19.18%, respectively. The Biofield Energy Treated 
formulation group showed suppression of TNF-α expression 
by 4.0% and 8.56% at 0.001053 and 0.1053 µg/mL, 
respectively as compared with the vehicle control. Overall, 
the test formulation showed immunosuppressive effect by 
inhibiting the concentration of TNF-α as compared with the 
vehicle control at four out of six tested concentrations. The 
Biofield Energy Treatment showed significant effect in 
altering the level of TNF-α as compared to the untreated test 
formulation. 
Overall, it can be concluded that the Biofield Energy 
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Healing Treatment potentiated the TNF-α inhibition, and 
showed immunosuppressive activity mainly at higher 
concentrations. TNF-α plays a major role in immune 
disorders and is also defined as a controlling factor for many 
other diseases [39]. Thus, it can be suggested that the 
Biofield Treated test formulation can be used in many 
inflammatory disorders and autoimmune diseases. 
 
Figure 3. Concentration-dependent effect on TNF-α by test formulation using splenocyte cells isolated from the Biofield Treated animals. For each 
concentration treatment, the level of TNF-α release was measured after 48-hours of treatment. All values are represented in pg/mL as mean ± SEM (**p≤0.01 
as compared with the untreated test formulation). 
3.2.2. Estimation of MIP-1α Expression 
The expression of MIP-1α on splenocyte cells isolated 
from the Biofield Energy Treated animals after exposure to 
the test formulation is shown in Figure 4. The results showed 
that MIP-1α secretion was inhibited in the presence of the 
test formulation as compared with the vehicle control group. 
However, the comparative effect of the test formulation on 
MIP-1α secretion in splenocyte cells showed significant 
alteration at all the tested concentrations. The untreated cells, 
LPS, Con-A, and vehicle control group showed values of 
MIP-1α as 88.32 ± 9.5, 988.32 ± 52.16, 337.93 ± 40.90, and 
1548.21 ± 54.73 pg/mL, respectively. However, the 
rapamycin at two different concentrations i.e. at 1 and 10 nM 
showed MIP-1α expression as 1083.43 and 1168.78 pg/mL, 
respectively. The untreated test formulation showed 
significant inhibition of MIP-1α secretion at 5 tested 
concentrations i.e. at 0.00001053, 0.0001053, 0.001053, 
0.1053, and 1.053 µg/mL by 9.89%, 9.89%, 15.69%, 2.94%, 
and 36.21%, respectively as compared to the vehicle control 
group. However, the Biofield Energy Treated test formulation 
showed suppression of MIP-1α in all the tested concentration 
i.e. 0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053 and 
1.053 µg/mL by 8.43%, 22.02%, 21.92%, 20.54%, 5.40%, 
and 19.82%, respectively as compared with the vehicle 
control group. The Biofield Energy Healing Treatment 
enhanced the immunosuppressive property of the test 
formulation in comparison with the untreated test 
formulation. Data suggest that the Biofield Energy Treated 
test formulation showed significant suppression of MIP-1α in 
4 tested concentrations out of 6, i.e. 0.0001053, 0.001053, 
0.01053, and 0.1053 µg/mL by 13.50%, 7.38%, 36.83% 
(p≤0.001), and 2.53%, respectively as compared with the 
untreated test formulation. 
 
Figure 4. Concentration-dependent inhibition of LPS mediated production of MIP-1α by the test formulation. For each concentration treatment, the levels of 
MIP-1α were measured after 48 hours of treatment. The values are represented in pg/mL as mean ± SEM (***p≤0.001 as compared with the untreated test 
formulation). 
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This suggests that the level of MIP-1α was inhibited at all 
the Biofield Energy Treated test formulation concentrations 
with respect to the vehicle control and showed significant 
inhibition up to 36.83% with respect to the untreated test 
formulation. The scientific reports suggest that the reduction 
of MIP-1α would be beneficial in minimizing the 
inflammatory responses in several diseases [40]. 
3.2.3. Estimation of IL-1β Expression 
The expression of IL-1β in the presence of the test 
formulation is presented in Figure 5. The results 
demonstrated the inhibition of IL-1β after treatment with the 
Biofield Treated and untreated test formulations as compared 
with the vehicle control group. However, the comparative 
effect of the Biofield Treated and untreated test formulations 
on IL-1β secretion in the Biofield Treated splenocytes 
showed significant inhibition at 4 out of 6 tested 
concentrations. The untreated cells, LPS, Con-A, and vehicle 
control group showed values of IL-1β as 8.18 ± 0.89, 51.65 ± 
4.04, 15.40 ± 2.75, and 38.23 ± 3.5 pg/mL, respectively. 
The untreated test formulation showed significant 
inhibition of IL-1β secretion in four tested concentrations i.e. 
at 0.00001053, 0.001053, 0.1053, and 1.053 µg/mL by 
22.94%, 23.07%, 38.71%, and 56.08%, respectively as 
compared with the vehicle control group. However, the 
Biofield Energy Treated test formulation group reported with 
inhibition of IL-1β secretion at four tested concentrations by 
22.94%, 23.07%, 38.71%, and 54.65% at 0.00001053, 
0.001053, 0.1053, and 1.053 µg/mL, respectively as 
compared with the vehicle control group. The comparative 
results suggest that the Biofield Energy Treatment 
significantly improved the immunosuppressive property of 
the test formulation at four concentrations as compared to the 
untreated test formulation. The significant inhibition of IL-1β 
secretion after the Biofield Treatment was reported at 
concentrations 0.0001053, 0.001053, 0.01053, and 0.01053 
µg/mL by 32.40%, 14.99%, 60.42%, and 15.15%, 
respectively as compared with the untreated formulation. 
 
Figure 5. Concentration-dependent effect of LPS mediated production of IL-1β by the test formulation. For each concentration treatment, the level of IL-1β 
release was measured in cell supernatant after 48-hours of treatment. All values are represented in pg/mL as mean ± SEM (*p≤0.05, as compared with the 
untreated test formulation). 
Overall, the results suggest that better immunosuppressive 
activity was reported at higher concentrations as compared to 
lower concentrations of the test formulation. The expression 
of IL-1β was decreased in the Biofield Energy Treated 
formulation at all the concentrations, except at concentration 
0.00001053 µg/mL. The immunological and inflammatory 
functions of IL-1β in controlling the immune response during 
infections are well-defined [41, 42]. Overall, the inhibitory 
effect might be the result of specific inhibition of NF-κB, a 
transcription factor involved in the activation of many 
inflammatory mediator genes. 
Herbomineral products have been reported to have 
beneficial results with minimal side effects in various 
diseases such as diabetes, indigestion, inflammation of the 
intestine, osteomalacia, blood disorders, infertility, potent 
revitalizer, etc. [43]. Due to its high safety profile and 
therapeutic effect, the scope of herbal and alternative and 
complimentary medicine has vastly increased worldwide 
[44]. Each of the individual components comprising the test 
formulation have been scientifically reported to have 
immunomodulatory effects. Ashwagandha is reported to 
inhibit the NF-κB and AP-1 transcription factors [45]. 
Minerals such as zinc directly influence the cytokines (IL-2, 
IL-6, IL-1β, and TNF-α) generation, in cases of deficiency 
[46]. Magnesium also affects the cytokines generation by 
activation of NF-κB, which has proven to be effective in 
inflammatory diseases [47]. Selenium plays an important role 
in inflammation by modulating the leukocytes effector 
functions like cytokines secretion, migration, adherence, and 
phagocytosis [48-50]. When applied to herbomineral 
formulations, Biofield Energy Healing Treatments can be a 
novel approach for immunosuppressive action. Overall, the 
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effect of the Biofield Energy Treated herbomineral 
formulation showed immunosuppressive effect on the level 
of tested cytokines and chemokines (TNF-α, IL-1β, and MIP-
1α) in splenocyte cells isolated from the Biofield Energy 
Treated mice, which supports the use of Biofield Energy 
Treated test formulation for various types of autoimmune 
disorders. 
4. Conclusions 
Based on the current findings of this study, the splenocyte 
cells isolated from the Biofield Energy Treated mice showed 
significant immunosuppressive effect on the tested cytokines 
(TNF-α, MIP-1α, and IL-1β) after administration of the 
Biofield Treated test formulation as compared with the 
untreated test formulation. MTT assay in the Biofield Treated 
splenocyte cells suggest that the Biofield Energy Treated 
formulation increased the cell viability by 3.17%, 5.07%, 
2.77%, and 6.61% at 0.0001053, 0.01053, 0.1053, and 1.053 
µg/mL, respectively as compared with the untreated test 
formulation. Further, the levels of cytokines were 
significantly suppressed in the Biofield Energy Treated test 
formulation group. TNF-α level was significantly inhibited 
by 16.72% at 0.1053 µg/mL in the Biofield Treated test 
formulation as compared with the untreated test formulation. 
However, the Biofield Energy Treated formulation group also 
showed low levels of TNF-α expression by 4.0% and 8.56% 
at 0.001053 and 0.1053 µg/mL, respectively as compared 
with the vehicle control group. In the case of MIP-1α, the 
Biofield Energy Treated test formulation showed significant 
suppression by 13.50%, 7.38%, 36.83% (p≤0.001), and 
2.53% at 0.0001053, 0.001053, 0.01053, and 0.1053 µg/mL, 
respectively as compared with the untreated test formulation. 
Besides, the levels of MIP-1α were also downregulated in all 
the tested concentrations of the test formulation by 8.43%, 
22.02%, 21.92%, 20.54%, 5.40%, and 19.82% at 
0.00001053, 0.0001053, 0.001053, 0.01053, 0.1053 and 
1.053 µg/mL, respectively as compared with the vehicle 
control group. Suppression of IL-1β expression was also 
reported in the Biofield Energy Treated test formulation 
group by 32.40%, 14.99%, 60.42% (p≤0.05), and 15.15% at 
0.0001053, 0.001053, 0.01053, and 0.01053 µg/mL, 
respectively as compared with the untreated formulation. 
On the basis of the experimental results of the various 
tested cytokines and their expression, significant 
immunosuppressive activity was reported in the new 
herbomineral formulation after treatment with The Trivedi 
Effect
® 
- Biofield Energy Healing (TEBEH) by the group of 
seven renowned Biofield Energy Healers. The Biofield 
Energy Treated test formulation can be used as an effective 
Complementary and Alternative Medicine (CAM) approach 
to prevent and treat immune-mediated diseases such as 
Irritable Bowel Syndrome, Rheumatoid arthritis, Ulcerative 
colitis and Crohn's disease, Stress, Asthma, and many more, 
with a safe therapeutic index. Biofield Energy Healing 
Treatments can also be utilized in organ transplants (for 
example kidney transplants, liver transplants and heart 
transplants), various autoimmune disorders such as Lupus, 
Addison Disease, Celiac Disease (gluten-sensitive 
enteropathy), Dermatomyositis, Graves’ Disease, Hashimoto 
Thyroiditis, Multiple Sclerosis (MS), Myasthenia Gravis, 
Pernicious Anemia, Aplastic Anemia, Sjogren Syndrome, 
Systemic Lupus Erythematosus, Alopecia Areata, 
Fibromyalgia, Vitiligo, Psoriasis, Scleroderma, Chronic 
Fatigue Syndrome, Vasculitis, and Type 1 Diabetes. Biofield 
Energy Healing can also be utilized for the anti-inflammatory 
disorders, stress prevention and management, anti-aging, and 
for the improvement of overall health and quality of life. 
Abbreviations: LPS: Lipopolysaccharide; DMSO: 
Dimethyl sulfoxide; FBS: Fetal bovine serum; MTT: 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; 
PBS: Phosphate buffer saline; ELISA: Enzyme-linked 
immunosorbent assay; NCCIH: National Center of 
Complementary and Integrative Health; CAM: 
Complementary and Alternative Medicine 
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